Martini, Dylan J.
Liu, Yuan
Shabto, Julie M.
Lewis, Colleen
Kline, Meredith R.
Collins, Hannah
Akce, Mehmet
Kissick, Haydn T.
Carthon, Bradley C.
Shaib, Walid L.
Alese, Olatunji B.
Pillai, Rathi N.
Steuer, Conor E.
Wu, Christina S.
Lawson, David H.
Kudchadkar, Ragini R.
Master, Viraj A.
El-Rayes, Bassel F.
Ramalingam, Suresh S.
Owonikoko, Taofeek K.
Harvey, R. Donald
Bilen, Mehmet Asim http://orcid.org/0000-0003-4003-1103
Funding for this research was provided by:
National Institutes of Health (P30CA138292)
Article History
Received: 17 December 2018
Accepted: 24 January 2019
First Online: 6 February 2019
Compliance with ethical standards
:
: Author M.A. Bilen has a consulting/advisory role with Exelixis, Nektar, and Sanofi and receives research funding from Bayer, Bristol-Myers Squibb, Genentech/Roche, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Peleton, and Pfizer.Author B.C. Carthon has a consulting/advisory role with Astellas Medivation, Pfizer, and Blue Earth Diagnostics and receives travel accommodations from Bristol-Myers Squibb.Author W.L. Shaib receives research funding from ArQule and Lilly.Author R. Pillai has a consulting/advisory role with Natera and AstraZeneca and receives travel accommodations from Genentech/Roche, Takeda, Novartis, and Clovis Oncology. She also receives research funding from Bristol-Myers Squibb.Author C. Wu receives honorarium from BioTheranostics and research funding from Amgen, Bristol-Myers Squibb, Vaccinex, and Boston Biomedical.Author R.R. Kudchadkar has a consulting/advisory role with Bristol-Myers Squibb, Novartis, and Array BioPharma. She also receives honorarium from Bristol-Myers Squibb and research funding from Merck.Author B.F. El-Rayes has a consulting/advisory role with Merrimack, BTG, Bayer, Loxo, and RTI Health Solutions. He is a member of the speakers’ bureau of Lexicon and Bristol-Myers Squibb. He also receives honorarium from Lexicon, RTI Health Solutions, and Bayer and received research funding from Taiho Pharmaceutical, Bristol-Myers Squibb, Boston Biomedical, Cleave Biosciences, Genentech, AVEO, Pfizer, Novartis, Hoosier Cancer Research Network, Five Prime Therapeutics, PPD Inc., Merck, and ICON Clinical Research.Author S.S Ramalingam has a consulting/advisory role with Amgen, Boehringer Ingelheim, Celgene, Genetech/Roche, Lilly/ImClone, Bristol-Myers Squibb, AstraZeneca, Abbvie, Merck, and Takeda and receives travel accommodations from EMD Serono, Pfizer, and AstraZeneca.Author T.K. Owonikoko has a consulting/advisory role with Novartis, Bristol-Myers Squibb, and MedImmune.Author D.J. Martini declares that he has no conflict of interest.Author Y. Liu declares that she has no conflict of interest.Author J.M. Shabto declares that she has no conflict of interest.Author <i>C. Lewis</i> declares that she has no conflict of interest.Author M.R. Kline declares that she has no conflict of interest.Author H. Collins declares that she has no conflict of interest.Author M. Akee declares that he has no conflict of interest.Author H.T. Kissick declares that he has no conflict of interest.Author O.B. Alese declares that he has no conflict of interest.Author C.E. Steuer declares that he has no conflict of interest.Author D.H. Lawson declares that he has no conflict of interest.Author V.A. Master declares that he has no conflict of interest.Author R.D. Harvey declares that he has no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.